Boule Diagnostics AB
The answer first
Does Boule Diagnostics beat the market?
No, Boule Diagnostics has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 5% of Nordic stocks
- Quality8
- Value53
- Trend2
No. 178 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash Boule Diagnostics keeps shrinks about 28% a year for 10 years.
Max for seven days
Follow Boule Diagnostics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Boule Diagnostics
Your first answer is free, no account needed.
Do you own Boule Diagnostics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Boule Diagnostics and a few more. Free, no card.
Super Stock+44.6%In short
- Boule Diagnostics has fallen 78.0% over the past year, including dividends.
- Overall, Boule Diagnostics ranks better than 5% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 93.2%. The price is 98.4% below its peak now.
Who owns Boule Diagnostics? See the major shareholders and their stakes
What do analysts think of Boule Diagnostics?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 5% of Nordic stocks.
No. 178 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 187 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity1.73
- Asset turnoverSales divided by everything the company owns0.93
- Return on equityProfit divided by equity−10.4%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 46 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.3
- P/SPrice divided by sales0.1
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flow1.7
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 187 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−62.9%
- 6 months−65.8%
- 9 months−70.6%
- 12 months−78.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Boule Diagnostics
3 funds we follow own Boule Diagnostics. The share is how much of the fund the stock makes up.
- Sweden3
From the funds' latest known holdings.
About Boule Diagnostics
Boule Diagnostics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 200 employees.
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. It operates through Diagnostics and OEM Clinical Diagnostic Solutions. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms.


See the full analysis of Boule Diagnostics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card